RT @SN_Oncology: Read 'Management of atrial fibrillation in patients taking targeted cancer therapies' from #CardioOncology for free using…
RT @SN_Oncology: Read 'Management of atrial fibrillation in patients taking targeted cancer therapies' from #CardioOncology for free using…
RT @SN_Oncology: Read 'Management of atrial fibrillation in patients taking targeted cancer therapies' from #CardioOncology for free using…
Read 'Management of atrial fibrillation in patients taking targeted cancer therapies' from #CardioOncology for free using #SharedIt: https://t.co/ve4y3Vf7eG #CancerTreament #Cancer #cancercare #Cardiology https://t.co/e9v3NorzN3
Are you an oncologist or cardiologist treating cancer patients with atrial fibrillation? Read our open access review: https://t.co/iyVoRM73Yr #SN_GrandChallenges https://t.co/j66WDWouxG
Are you an oncologist or cardiologists treating cancer patients with atrial fibrillation? Read our open access review: https://t.co/iyVoRM73Yr #SN_GrandChallenges https://t.co/JkxkmNYbG7
"...an international retrospective study was performed to define the clinical characteristics of patients treated for CLL who developed AF [atrial fibrillation] on ibrutinib... 76% of patients developed AF during the first year of ibrutinib therapy." https
RT @Office_j: 【雑記】Cardio-Oncol誌に、癌標的療法下のAF例への抗凝固療法に関する総説。 https://t.co/9BlQ3IkfdG https://t.co/Y9G5A7SbGB
【雑記】Cardio-Oncol誌に、癌標的療法下のAF例への抗凝固療法に関する総説。 https://t.co/9BlQ3IkfdG https://t.co/Y9G5A7SbGB
RT @Office_j: 【雑記】Cardio-Oncology誌に、抗癌剤治療下のAF治療に関する総説。癌診断から1.8%/年がAF発症。ワルファリンのINR管理は困難。DOACは十分なデータなし。各種の薬剤相互作用あり。 https://t.co/vU3Vm8K0o6…
【雑記】Cardio-Oncology誌に、抗癌剤治療下のAF治療に関する総説。癌診断から1.8%/年がAF発症。ワルファリンのINR管理は困難。DOACは十分なデータなし。各種の薬剤相互作用あり。 https://t.co/vU3Vm8K0o6 https://t.co/PKcQ96AeKB